For your adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment
SAFETY AND TOLERABILITY PROFILE DEMONSTRATED IN MULTIPLE CLINICAL TRIALS1
Adverse reactions with a frequency ≥10% in patients with chronic ITP treated with
DOPTELET® (avatrombopag)—pooled data from clinical trials*
*The safety of DOPTELET in adults with chronic ITP was evaluated in two Phase 3 trials (one randomized, double-blind, placebo-controlled trial, and one randomized, double-blind, active-controlled trial) and two Phase 2 trials (one randomized, double-blind, placebo-controlled, dose-ranging trial and one open-label extension trial) in 161 patients with chronic ITP. Analysis included 128 patients who received 2.5 to 40 mg of DOPTELET once daily for a median exposure of 29.1 weeks, and 22 patients who received placebo for a median exposure of 5.9 weeks.1,2
1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc.
2. Data on file. Dova Pharmaceuticals, Inc.